Methylene Blue for the Prevention of Hypotension During Hemodialysis

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
Hypotension is a common complication of intermittent renal replacement therapy. Methylene blue, an inhibitor of nitric oxide synthesis, has been suggested to improve hemodynamics during renal replacement therapy in ambulatory patients, but evidence is lacking for critically ill patients. This trial will assess whether methylene blue can improve hemodynamics and blood pressure for patients with shock requiring renal replacement therapy.
Epistemonikos ID: 9274e2159ecfef15a813a1e52b57b451da029670
First added on: May 09, 2024